Basin Korea’s ‘Tevimbraju’ succeeds in first payment challenge

(Health Korea News / Lee Chang-yong) Beigene Korea’s esophageal squamous cell cancer treatment ‘Tevimbraju (ingredient name: tislelizumab)’ succeeded in the first challenge for health insurance coverage.

The Health Insurance Review and Assessment Service (HIRA) held the ‘2025 1st Pharmaceutical Reimbursement Evaluation Committee (Pharmaceutical Evaluation Committee)’ held on the 9th, regarding Beigene Korea’s ‘Tevimbra Injection 100mg (ingredient name: tislelizumab)’ on ‘adequacy of benefits’. ‘There is this,’ he deliberated. The efficacy and effectiveness of Tebimbraju, recognized by the Pharmaceutical Review Committee, is the treatment of esophageal squamous cell cancer.

On this day, the Pharmaceutical Review Committee also reviewed Handok’s ‘Femazyre Tablets 4.5, 9, and 13.5mg (ingredient name: Femigatinib)’ as appropriate for the treatment of ‘FGFR2 fusion or rearrangement cholangiocarcinoma’.

Boehringer Ingelheim Korea’s ‘Ofev Soft Capsule 100,150mg (ingredient name: nintedanib)’ is applied for three indications: 1. Idiopathic pulmonary fibrosis 2. Interstitial lung disease associated with anterior sclerosis 3. Progressive pulmonary fibrosis. It was reviewed that benefits were appropriate for ‘pulmonary disease’ and ‘advanced pulmonary fibrosis’.

#Risk sharing agreement drug review results

Regarding Pfizer Korea’s application to expand the scope of reimbursement for ‘Rovicua Tablet 25,100mg (ingredient name: Rolatinib)’ for the treatment of ‘anaplastic lymphoma phosphorylase (ALK)-positive metastatic non-small cell lung cancer’, the Pharmaceutical Review Committee accepted ‘the amount below the evaluation amount’. He added, “There is appropriateness in expanding the city’s benefit range.”

‘Acceptance below the assessed amount’ means that the pharmaceutical company will recognize the adequacy of the benefit if it accepts the amount suggested by the Pharmaceutical Review Committee. In this case, most pharmaceutical companies accept the Pharmaceutical Trade Commission’s opinion and reapply for medical care benefits at a lower amount than the original.

The Director of HIRA evaluates the adequacy of pharmaceutical benefits through deliberation by the Pharmaceutical Benefits Evaluation Committee in accordance with Article 11-2 of the National Health Insurance Nursing Care Benefit Standards Rule. Drugs that have been recognized as appropriate can receive health insurance benefits according to the new benefit standards if they pass future drug price negotiations with the National Health Insurance Corporation and the review of the Health Insurance Policy Deliberation Committee of the Ministry of Health and Welfare.

(Results of deliberation on the adequacy of medical care benefits for drugs requested for decision)

(Results of deliberation on the appropriateness of expanding the scope of use of risk-sharing contract drugs)

Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited